Schizophrenia Invest Advisor

Anavex Life Sciences Commences Phase 2 Trial of ANAVEX®3-71 for Schizophrenia Mar 18, 2024

Neumora Therapeutics Embarks on Phase 1 Clinical Study for NMRA-266, Targeting Schizophrenia Treatment Nov 27, 2023